Baili Pharmaceutical
Shanghai, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A clinical-stage biotech developing novel small molecule drugs for oncology and metabolic diseases.
OncologyMetabolic
Technology Platform
A structure-based drug design platform leveraging computational and structural biology to develop novel small molecule therapeutics.
Opportunities
Potential to address significant patient populations in China and globally with targeted, orally available therapies.
Risk Factors
Clinical trial failure risk is high, and the company faces intense competition for funding, talent, and patient enrollment.
Competitive Landscape
Operates in the highly crowded oncology small molecule space, requiring highly differentiated data to stand out to partners and investors.